50-100

Title Average Ratingsort ascending
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-s 100.00%
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. 100.00%
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate c 100.00%
Psychodynamic psychotherapy, therapeutic touch and cancer. A review of the method of intervention and studv of 75 cases 100.00%
Hibiscus sabdariffa L. Tea (Tisane) Lowers Blood Pressure in Prehypertensive and Mildly Hypertensive Adults 90.00%
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent 90.00%
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. 90.00%
GROUNDING THE HUMAN BODY TO NEUTRALIZE BIO-ELECTRICAL STRESS FROM STATIC ELECTRICITY AND EMFs. 90.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced esoph 90.00%
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial 85.00%
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from 80.00%
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid 80.00%
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocy.. 80.00%
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glio 80.00%
Clinical studies of Ukrain in terminal cancer patients (phase II) 80.00%
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a .. 80.00%
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer 80.00%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 80.00%
Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha. 70.00%
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone 70.00%
Oncolytic virus therapy for prostate cancer. 70.00%
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. 70.00%
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. 70.00%
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal ca. patients 70.00%
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. 65.00%
Early outcomes following low dose naltrexone enhancement of opioid detoxification. 60.00%
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. 60.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera 50.00%
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit 50.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. 30.00%
Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment 30.00%
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced... 30.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%